Stockscreener 앱 받기
316.73
0.98%
-3.13
시간 외 거래:
319.61
2.88
+0.91%
United Therapeutics Corp 주식(UTHR)의 최신 뉴스
United Therapeutics director sells $796,990 in stock - Investing.com India
United Therapeutics director sells $1.55 million in stock By Investing.com - Investing.com Canada
United Therapeutics director sells $1.55 million in stock - Investing.com India
Market Turbulence? These 20 Stocks Boast a Perfect Piotroski Score and 40%+ Upside - Investing.com
United Therapeutics price target lowered to $314 from $328 at BofA - TipRanks
Exosome Therapy Market Market Is Booming Worldwide 2025-2032 | - openPR
Is United Therapeutics Corporation (UTHR) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
United Therapeutics president Michael Benkowitz sells $640k in stock By Investing.com - Investing.com Australia
For patients needing transplants, hope arrives on tiny hooves - The Spokesman Review
United Therapeutics president Michael Benkowitz sells $640k in stock - Investing.com
What Will United Therapeutics Reveal at the Leerink Conference? Key Details for Investors - StockTitan
Top Executives Cash In on United Therapeutics Stock! - TipRanks
Ray Kurzweil Sells 15,000 Shares of United Therapeutics Corp - GuruFocus.com
United Therapeutics director Thompson sells $795,837 in stock By Investing.com - Investing.com Canada
United Therapeutics director Thompson sells $795,837 in stock - Investing.com India
Silver Spring's United Therapeutics to Begin Clinical Study of Groundbreaking UKidney™ (Pig Organ) Transplant - The MoCoShow
Q2 EPS Estimate for United Therapeutics Lowered by Analyst - Defense World
Oppenheimer Asset Management Inc. Sells 6,988 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Bank of New York Mellon Corp Sells 1,693 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Receives FDA Approval for Pig Organ Clinical Trials - Source of the Spring
United Therapeutics (NASDAQ:UTHR) Earns “Buy” Rating from HC Wainwright - Defense World
United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by New York State Common Retirement Fund - MarketBeat
Weil Company Inc. Has $449,000 Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics (NASDAQ:UTHR) Releases Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
United Therapeutics (NASDAQ:UTHR) Shares Gap Down Following Insider Selling - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Stock Position Boosted by Fjarde AP Fonden Fourth Swedish National Pension Fund - MarketBeat
United Therapeutics (NASDAQ:UTHR) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
Los Angeles Capital Management LLC Has $36.55 Million Stake in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Truist Financial Corp Sells 2,920 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz Sells 10,000 Shares - MarketBeat
Atria Wealth Solutions Inc. Invests $412,000 in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
United Therapeutics price target lowered to $420 from $430 at Leerink - Yahoo Finance
Lung transplant technology collaboration between Mayo Clinic Florida and United Therapeutics - Florida Trend
United Therapeutics Corp. Reports Record Revenue and Growth - TipRanks
United Therapeutics Corp. to Host Earnings Call - ACCESS Newswire
United Therapeutics Reports Record Revenue in Q4 2024, Advances Strategic Growth - HPBL
United Therapeutics Corporation (NASDAQ:UTHR) Q4 2024 Earnings Call Transcript - Insider Monkey
Goldman Sachs cuts United Therapeutics stock target to $293 By Investing.com - Investing.com Australia
Goldman Sachs cuts United Therapeutics stock target to $293 - Investing.com
United Therapeutics: Q4 Earnings Snapshot - Thehour.com
United Therapeutics Corp (UTHR) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insig - GuruFocus.com
United Therapeutics Reports Record 2024 Financial Results - TipRanks
United Therapeutics Enters Oversold Territory (UTHR) - Nasdaq
United Therapeutics (UTHR) Shares Cross Below 200 DMA - Nasdaq
United Therapeutics Stock Down Despite Q4 Earnings & Sales Beat - Yahoo Finance
Earnings call transcript: United Therapeutics Q4 2024 earnings miss impacts stock - Investing.com
United Therapeutics (NASDAQ:UTHR) Reports Q4 In Line With Expectations - Yahoo Finance
United Therapeutics: Q4 Earnings Snapshot -February 26, 2025 at 06:49 am EST - Marketscreener.com
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Earnings Flash (UTHR) United Therapeutics Posts Q4 Revenue $735.9M, vs. FactSet Est of $734.7M - Marketscreener.com
UNITED THERAPEUTICS Corp SEC 10-K Report - TradingView
GraniteShares Advisors LLC Takes Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
How United Therapeutics Drove 24% Revenue Growth in 2024Key Products and Pipeline Updates - StockTitan
What To Expect From United Therapeutics’s (UTHR) Q4 Earnings - Yahoo Finance
United Therapeutics: A Unique Business With High Margins And Expansion Potential - Seeking Alpha
1.06%
0.03%
자본화:
|
볼륨(24시간):